WO2017100305A8 - Composition of antibody construct-agonist conjugates and methods of use thereof - Google Patents

Composition of antibody construct-agonist conjugates and methods of use thereof Download PDF

Info

Publication number
WO2017100305A8
WO2017100305A8 PCT/US2016/065353 US2016065353W WO2017100305A8 WO 2017100305 A8 WO2017100305 A8 WO 2017100305A8 US 2016065353 W US2016065353 W US 2016065353W WO 2017100305 A8 WO2017100305 A8 WO 2017100305A8
Authority
WO
WIPO (PCT)
Prior art keywords
antibody construct
methods
composition
agonist conjugates
disclosed
Prior art date
Application number
PCT/US2016/065353
Other languages
French (fr)
Other versions
WO2017100305A3 (en
WO2017100305A2 (en
Inventor
Peter Armstrong Thompson
Badreddin EDRIS
Original Assignee
Opi Vi - Ip Holdco Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/173,075 external-priority patent/US20170158772A1/en
Application filed by Opi Vi - Ip Holdco Llc filed Critical Opi Vi - Ip Holdco Llc
Priority to DE212016000029.2U priority Critical patent/DE212016000029U1/en
Priority to EP16873755.9A priority patent/EP3386536A4/en
Priority to CA3007311A priority patent/CA3007311A1/en
Priority to US15/624,441 priority patent/US20170298139A1/en
Publication of WO2017100305A2 publication Critical patent/WO2017100305A2/en
Publication of WO2017100305A3 publication Critical patent/WO2017100305A3/en
Publication of WO2017100305A8 publication Critical patent/WO2017100305A8/en
Priority to US17/066,776 priority patent/US20210139604A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Various antibody construct compositions are disclosed. The compositions of antibody construct-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and used of the antibody construct-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer. A genus of STING agonist compounds and method of synthesis is also disclosed.
PCT/US2016/065353 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof WO2017100305A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE212016000029.2U DE212016000029U1 (en) 2015-12-07 2016-12-07 Compositions of antibody construct agonist conjugates
EP16873755.9A EP3386536A4 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof
CA3007311A CA3007311A1 (en) 2015-12-07 2016-12-07 Compositions of antibody construct-agonist conjugates and methods of use thereof
US15/624,441 US20170298139A1 (en) 2015-12-07 2017-06-15 Compositions of antibody construct-agonist conjugates and methods of use thereof
US17/066,776 US20210139604A1 (en) 2015-12-07 2020-10-09 Compositions of antibody construct-agonist conjugates and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562264260P 2015-12-07 2015-12-07
US62/264,260 2015-12-07
US15/173,075 2016-06-03
US15/173,075 US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof
US201662371141P 2016-08-04 2016-08-04
US62/371,141 2016-08-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/173,075 Continuation US20170158772A1 (en) 2015-12-07 2016-06-03 Compositions of antibody construct - agonist conjugates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/624,441 Continuation US20170298139A1 (en) 2015-12-07 2017-06-15 Compositions of antibody construct-agonist conjugates and methods of use thereof

Publications (3)

Publication Number Publication Date
WO2017100305A2 WO2017100305A2 (en) 2017-06-15
WO2017100305A3 WO2017100305A3 (en) 2017-07-20
WO2017100305A8 true WO2017100305A8 (en) 2017-09-08

Family

ID=59013332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/065353 WO2017100305A2 (en) 2015-12-07 2016-12-07 Composition of antibody construct-agonist conjugates and methods of use thereof

Country Status (4)

Country Link
EP (1) EP3386536A4 (en)
CA (1) CA3007311A1 (en)
DE (1) DE212016000029U1 (en)
WO (1) WO2017100305A2 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
MA42608A (en) 2015-08-13 2018-06-20 Merck Sharp & Dohme CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS (INTERFERON GENE STIMULATOR)
CN114751950A (en) 2016-03-18 2022-07-15 免疫传感器公司 Cyclic dinucleotide compounds and methods of use
KR102590454B1 (en) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody-Adjuvant Conjugate
MA46452B1 (en) 2016-10-04 2021-10-29 Merck Sharp & Dohme Benzo [b] thiophene compounds as sting agonists
JOP20170192A1 (en) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co Cyclic dinucleotide
WO2018144955A1 (en) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Construct-peptide compositions and methods of use thereof
AR113224A1 (en) * 2017-04-28 2020-02-19 Novartis Ag ANTIBODY CONJUGATES INCLUDING A STING AGONIST
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2019027858A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. BENZO[b]THIOPHENE STING AGONISTS FOR CANCER TREATMENT
JP2020529421A (en) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Combination of PD-1 antagonist and benzo [b] thiophene STING agonist for the treatment of cancer
CN107365361B (en) * 2017-08-21 2020-05-19 中国药科大学 Repeat domain anchored proteins that bind to PD-L1 and uses thereof
ES2945140T3 (en) * 2017-08-31 2023-06-28 Bristol Myers Squibb Co Cyclic dinucleotides as anticancer agents
EP3676279B1 (en) * 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019051489A1 (en) * 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US11584774B2 (en) 2017-09-11 2023-02-21 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
PE20210156A1 (en) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co STING MODULATING COMPOUNDS AND METHODS OF PREPARATION AND USE
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3505188A1 (en) * 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
TWI793294B (en) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting agonist compounds
MA52754A (en) 2018-05-25 2021-04-14 Incyte Corp HETEROCYCLIC TRICYCLIC COMPOUNDS AS STING ACTIVATORS
WO2020028566A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
SG11202101526YA (en) 2018-09-06 2021-03-30 Daiichi Sankyo Co Ltd Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
EP3937984A1 (en) 2019-03-15 2022-01-19 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
AU2020286523A1 (en) * 2019-06-03 2022-02-03 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
EP3980057A1 (en) 2019-06-04 2022-04-13 Institut Curie Methods of producing shiga toxin b-subunit (stxb) monomers and oligomers, and uses thereof
BR112022000854A2 (en) 2019-07-19 2022-03-08 Immunesensor Therapeutics Inc Antibody-sting agonist conjugates and their use in immunotherapy
TW202120500A (en) 2019-08-02 2021-06-01 美商梅爾莎納醫療公司 Sting agonist compounds and methods of use
EP4025254A1 (en) * 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021110987A1 (en) 2019-12-06 2021-06-10 Life & Soft Methods and apparatuses for diagnosing cancer from cell-free nucleic acids
CN111233850B (en) * 2020-01-21 2022-09-23 南开大学 Naphthol derivative containing benzothiazole amino and heteroaryl and preparation method and application thereof
EP4106819A1 (en) 2020-02-21 2022-12-28 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
TWI851879B (en) 2020-03-06 2024-08-11 日商第一三共股份有限公司 Antibody-drug conjugates containing novel cyclic dinucleotide derivatives
CA3171408A1 (en) 2020-03-13 2021-09-16 Martine Caroff Detoxified lipopolysaccharides (lps), naturally non-toxic lps, and uses thereof
JP2023533111A (en) 2020-05-15 2023-08-02 イミューンセンサー セラピューティクス、インコーポレイテッド STING agonist combination therapy with immune checkpoint inhibitors
EP4175673A1 (en) 2020-07-01 2023-05-10 ARS Pharmaceuticals Inc. Anti-asgr1 antibody conjugates and uses thereof
EP3943505A1 (en) 2020-07-22 2022-01-26 Encefa Cd38-binding cd31 peptides and uses thereof
EP4209506A4 (en) 2020-09-02 2024-10-09 Daiichi Sankyo Co Ltd Novel endo-?-n-acetylglucosaminidase
AU2021374958A1 (en) 2020-11-09 2023-06-22 Takeda Pharmaceutical Company Limited Antibody drug conjugates
EP4255475A1 (en) 2020-12-02 2023-10-11 Institut Curie Functionalized shiga toxin b-subunit (stxb) proteins and conjugates thereof
CA3208783A1 (en) 2021-02-26 2022-09-01 Brenus Pharma Nonautologous multi-stressed cancer cells and uses thereof for vaccinating and treating cancers
JP2024526874A (en) 2021-07-23 2024-07-19 イミューンセンサー セラピューティクス、インコーポレイテッド STING agonist combination therapy with cytokines
EP4401842A1 (en) 2021-09-16 2024-07-24 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
CN118524854A (en) * 2021-12-17 2024-08-20 北京加科思新药研发有限公司 Compound-linker constructs comprising novel compounds useful as STING agonists and uses thereof
KR20240155298A (en) 2022-03-02 2024-10-28 다이이찌 산쿄 가부시키가이샤 Method for producing Fc-containing molecules
WO2024193253A1 (en) * 2023-03-18 2024-09-26 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-her3/muc1 antibodies and uses thereof
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920561A1 (en) * 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for thrombin and methods of use
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
JP3696884B2 (en) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド Enhancement of drug efficacy by deuteration
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
PE20142406A1 (en) * 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
EP3092255A4 (en) * 2014-01-10 2017-09-20 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating egfr expressing tumors

Also Published As

Publication number Publication date
WO2017100305A3 (en) 2017-07-20
WO2017100305A2 (en) 2017-06-15
EP3386536A2 (en) 2018-10-17
CA3007311A1 (en) 2017-06-15
DE212016000029U1 (en) 2017-07-30
EP3386536A4 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
WO2017100305A8 (en) Composition of antibody construct-agonist conjugates and methods of use thereof
AR125320A2 (en) CRYSTALLINE COMPOUND, METHOD OF PREPARATION AND COMPOSITION INCLUDING IT
WO2018140831A3 (en) Tumor targeting conjugates and methods of use thereof
EP3642182A4 (en) Compounds, compositions and methods for synthesis
WO2017087901A3 (en) Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
WO2017214458A3 (en) Anti-cd98 antibodies and antibody drug conjugates
MX2019014514A (en) Compounds for treating huntington's disease.
WO2017173415A3 (en) Saccharide-polypeptide conjugate compositions and methods of use thereof
EP4279071A3 (en) Novel cannabinoid formulations
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2015192127A3 (en) Formulated receptor polypeptides and related methods
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
WO2015164392A8 (en) Novel anti-rnf43 antibodies and methods of use
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
WO2015054600A3 (en) Glycan-interacting compounds and methods of use
MX2019003818A (en) 3-phenyl-2,3,4,8,9,10-hexahydropyrano[2,3-f]chromene derivative and method for synthesizing optical isomer thereof.
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
WO2017042828A3 (en) Process for the preparation of selexipag
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
WO2016102672A3 (en) Inhibitors of akt kinase

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 212016000029

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873755

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3007311

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2016873755

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016873755

Country of ref document: EP

Effective date: 20180709

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873755

Country of ref document: EP

Kind code of ref document: A2